A simple dose gradient measurement tool to complement the conformity index

Restricted access

✓A dose gradient index (GI) is proposed that can be used to compare treatment plans of equal conformity. The steep dose gradient outside the radiosurgical target is one of the factors that makes radiosurgery possible. It therefore makes sense to measure this variable and to use it to compare rival plans, explore optimal prescription isodoses, or compare treatment modalities.

The GI is defined as the ratio of the volume of half the prescription isodose to the volume of the prescription isodose. For a plan normalized to the 50% isodose line, it is the ratio of the 25% isodose volume to that of the 50% isodose volume.

The GI will differentiate between plans of similar conformity, but with different dose gradients, for example, where isocenters have been inappropriately centered on the edge of the target volume.

In a retrospective series of 50 dose plans for the treatment of vestibular schwannoma, the optimal prescription isodose was assessed. A mean value of 40% (median 38%, range 30–61%) was calculated, not 50% as might be anticipated. The GI can show which of these prescription isodoses will give the steepest dose falloff outside the target.

When planning a multiisocenter treatment, there may be a temptation to place some isocenters on the edge of the target. This has the apparent advantage of producing a plan of good conformity and a predictable prescription isodose; however, it risks creating a plan that has a low dose gradient outside the target. The quality of this dose gradient is quantified by the GI.

Abbreviations used in this paper: GI = gradient index; GKS = Gamma Knife surgery; PIV = prescription isodose volume.

Article Information

Address reprint requests to: Ian Paddick, M.Sc., Gamma Knife Centre, Cromwell Hospital, Cromwell Road, London, SW5 OTU, United Kingdom. email: ian@physicsconsulting.co.uk.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Neuroimage of a treatment plan for a cavernous sinus meningioma, revealing the 75%, 50%, 25%, 15%, and 10% isodose lines. There is excellent conformity of the 50% isodose line and the periphery of the target; however, the 25% isodose volume covers a significant volume of brainstem and temporal lobe.

  • View in gallery

    Neuroimages of three plans for treatment for the same vestibular schwannoma. All three plans have equal conformity indices as described by Paddick17 (PCI), but the volumes enclosing half the prescription dose are markedly at variance. a: Plan 1 consists of 5 × 14–mm isocenters prescribed to the 46% isodose, PCI = 0.87, PIV46%= 3.7 cm3, PIV23%=12.2 cm3, GI = 12.2/3.7 = 3.30. b: Plan 2 consists of 16 × 8–mm isocenters prescribed to the 50% isodose, PCI = 0.87, PIV50%= 3.6 cm3, PIV25%= 10.6 cm3, GI = 10.6/3.6 = 2.94. c: Plan 3 consists of 2 × 14–mm collimators, 2 × 8–mm collimators, and a single 4-m collimator, PCI = 0.87, PIV42%= 3.7 cm3, GI = 9.8/3.7 = 2.65. The prescription isodose of 42% has the greatest deviation from the gold standard of 50%, but nevertheless has the sharpest dose falloff outside the target. This contradicts the generally held belief that many small isocenters and a 50% isodose line produce a sharper dose falloff.

  • View in gallery

    Neuroimage of dose planning for a vestibular schwannoma. The 45% and 95% isodose lines are shown. The addition of the final 8-mm isocenter (large circle) causes contraction of the isodoses, because of its proximity to the hot spot. The dose planner has three choices: 1) Move the 8-mm isocenter further out into the brainstem. 2) Accept a renormalized plan and use a lower prescription isodose. 3) Replace the 8-mm isocenter with 4-mm isocenters to move the isodose line closer to the border (no need to renormalize the plan).

  • View in gallery

    Graph showing the variation of the proposed GI against the prescription isodose line for individual collimators.

  • View in gallery

    Graph showing the variation of the GI with prescription isodose diameter in the x and y planes for the four single collimators.

  • View in gallery

    Graph showing the variation of mean GI with prescription isodose for 50 vestibular schwannoma treatment plans. The flat bottom of the curve shows 1.5% variation in the GI between the 33% and 43% isodose lines.

  • View in gallery

    Graph showing the optimal GI plotted against the number of isocenters for a series of 50 vestibular schwannoma treatment plans.

  • View in gallery

    A simplified dose profile along a line through a multiisocenter dose plan. When planning using multiple isocenters, the maximum dose gradient is still at approximately the 70% isodose line of each individual isocenter. As multiple isocenter configurations produce maxima that are much higher than the individual isocenter maxima, the renormalization of the plan means that the area of steepest dose gradient is found at much lower isodose volumes. In this example it is found at 40% of the peak dose of the plan.

References

1

Andrews DSuarez OGoldman HDownes MBednarz GCorn B: Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution.Int J Radiat Oncol Biol Phys 50:126512782001

2

Bhatnagar AKFlickinger JCKondziolka DLunsford LD: Stereotactic Radiosurgery for four or more intracranial metastases.Int J Radiat Oncol Biol Phys 64:8989032006

3

Chen JCPetrovich ZO'Day SMorton DEssner RGiannotta SL: Stereotactic radiosurgery in the treatment of metastatic disease in the brain.Neurosurgery 47:2682792000

4

Chung WYLiu KDShiau CYWu HWang LGuo W: Gamma Knife surgery for vestibular schwannoma: 10-year experience of 195 Cases.J Neurosurg (Suppl) 102:87962005

5

Flickinger JCKondziolka DLunsford LDKassam APhuong LKLiščák R: Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients.Int J Radiat Oncol Biol Phys 46:114311482000

6

Flickinger JCKondziolka DNiranjan ALunsford LD: Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods.J Neurosurg 94:162001

7

Fuss MDebus JLohr FHuber PRhein BEngenhart-Cabillic R: Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas.Int J Radiat Oncol Biol Phys 48:138113872000

8

Hasegawa TKondziolka DFlickinger JCGermanwala ALunsford LD: Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy? Neurosurgery 52:131813262003

9

Hasegawa TKida YKobayashi TYoshimoto MMori YYoshida J: Long-term outcome in patients with vestibular schwannoma treated using Gamma Knife surgery: 10-year follow up.J Neurosurg 102:10162005

10

Korytko TRadivoyevitch TColussi BWessels VPillai RMaciunas R: 12 Gy Gamma Knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors.Int J Radiat Oncol Biol Phys 64:4194242006

11

Liščák RNovotný JUrgošik DVladyka VŠimonová G: Statistical analysis of risk factors after Gamma Knife radiosurgery of acoustic neurinomas.Radiosurgery 3:2052132000

12

Lunsford LDNiranjan AFlickinger JCMaitz AKondziolka D: Radiosurgery of vestibular schwannoma: summary of experience in 829 cases.J Neurosurg (Suppl) 102:1951992005

13

Massager NNissim ODelbrouck CDevriendt DDavid PDesmedt F: Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery.Int J Radiat Oncol Biol Phys 64:133113402006

14

Mindermann T: Tumor recurrence and survival following Gamma Knife surgery for brain metastases.J Neurosurg (Suppl) 102:2872882005

15

Nakamura JLVerhey LJSmith VPetti PLambourn KLarson D: Dose conformity of Gamma Knife radiosurgery and risk factors for complications.Int J Radiat Oncol Biol Phys 51:131313192001

16

Nam TKLee JIJung YJIm YSAn HYNam DH: Gamma Knife surgery for brain metastases in patients harboring four or more lesions: survival and prognostic factors.J Neurosurg (Suppl) 102:1471502005

17

Paddick I: A simple scoring ratio to index the conformity of radiosurgical treatment plans.J. Neurosurg (Suppl 3) 93:2192222000

18

Pan HCSheehan JStroila MSteiner MSteiner L: Gamma Knife surgery for brain metastases from lung cancer.J Neurosurg (Suppl) 102:1281332005

19

Plowman PN: Post-radiation sensorineuronal hearing loss.Int J Radiat Oncol Biol Phys 52:5895912002

20

Prasad DSteiner MSteiner L: Gamma Knife surgery for vestibular schwannoma.J Neurosurg (Suppl 3) 93:32362000

21

Rowe JGRadatz MWRWalton LSoanes TRodgers JKemeny AA: Clinical experience with Gamma Knife radiosurgery in the management of vestibular schwannoma secondary to type 2 neurofibromatosis.J Neurol Neurosurg Psychiatry 74:128812932003

22

Sampath PRini DLong D: Microanatomical variations in the cerebellopontine angle associated with vestibular schwannomas (acoustic neuromas): a retrospective study of 1006 consecutive cases.J Neurosurg 92:70782000

23

Serizawa TIuchi TOno JSaeki NOsato KOdaki M: Gamma Knife treatment for multiple brain tumors compared with whole-brain radiation therapy.J Neurosurg (Suppl 3) 93:32362000

24

Shaw EKline RGillin MSouhami LHirschfeld ADinapoli R: Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines.Int J Radiat Oncol Biol Phys 27:123112391993

25

Shaw EScott CSouhami LDinapoli RKline RLoeffler JFarnan N: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05.Int J Radiat Oncol Biol Phys 47:2912982000

26

Shaw EScott CSouhami LDinapoli RKline RLoeffler J: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of the RTOG protocol 90-05.Int J Radiat Oncol Biol Phys 47:2912982000

27

Sneed PKSuh JHGoetsch SJSanghavi SNChappell RBuatti JM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases.Int J Radiat Oncol Biol Phys 53:5195262002

28

Van Eck AHorstmann G: Increased functional hearing after Gamma Knife surgery for vestibular schwannoma.J Neurosurg (Suppl) 102:2042062005

29

Varlotto JMFlickinger JCNiranjan ABhatnagar AKKondziolka DLunsford LD: Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases.Int J Radiat Oncol Biol Phys 57:4524642003

30

Wagner THBova FJFriedman WABuatti JMBouchet LGMeeks SL: A simple and reliable index for scoring rival stereotactic radiosurgery plans.Int J Radiat Oncol Biol Phys 57:114111492003

31

Wowra BMuacevic AJess-Hempen AHempel JMMüller-Schunk STonn JC: Outpatient Gamma Knife surgery for vestibular schwannoma: definition of the therapeutic profile based on a 10-year experience.J Neurosurg (Suppl) 102:1141182005

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 20 20 18
Full Text Views 153 153 44
PDF Downloads 73 73 22
EPUB Downloads 0 0 0

PubMed

Google Scholar